1.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
2.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
3.
International Textbook of Diabetes Mellitus. 4th ed. John Wiley & Sons, Incorporated; 2015. http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437
4.
Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng17
5.
Type 2 diabetes in adults: management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng28
6.
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet. Published online February 2017. doi:10.1016/S0140-6736(17)30058-2
7.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383(9911):69-82. doi:10.1016/S0140-6736(13)60591-7
8.
Matheus AS de M, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes M de B. Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension. 2013;2013:1-15. doi:10.1155/2013/653789
9.
Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335
10.
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947
11.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
12.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
13.
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743
14.
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. doi:10.1007/s00125-009-1470-0
15.
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine. 2011;364(9):818-828. doi:10.1056/NEJMoa1006524
16.
Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340(jan08 1):b5444-b5444. doi:10.1136/bmj.b5444
17.
Duckworth W, Abraira C, Moritz T, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine. 2009;360(2):129-139. doi:10.1056/NEJMoa0808431
18.
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;372(23):2197-2206. doi:10.1056/NEJMoa1414266
19.
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2560-2572. doi:10.1056/NEJMoa0802987
20.
Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694-700. doi:10.2337/dc15-2322
21.
Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? Diabetes Care. 2016;39(Supplement 2):S187-S195. doi:10.2337/dcS15-3023
22.
Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine. 2008;358(6):580-591. doi:10.1056/NEJMoa0706245
23.
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993;329(14):977-986. doi:10.1056/NEJM199309303291401
24.
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine. 2005;353(25):2643-2653. doi:10.1056/NEJMoa052187
25.
Orchard TJ, Nathan DM, Zinman B, et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA. 2015;313(1). doi:10.1001/jama.2014.16107
26.
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298-2307. doi:10.1007/s00125-016-4065-6
27.
Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports. 2013;13(3):403-410. doi:10.1007/s11892-013-0371-2
28.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
29.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
30.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343(jul26 1):d4169-d4169. doi:10.1136/bmj.d4169
31.
Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet. 2009;373(9677):1765-1772. doi:10.1016/S0140-6736(09)60697-8
32.
Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine. Published online 18 April 2017. doi:10.1111/dme.13364
33.
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 2017;376(15):1407-1418. doi:10.1056/NEJMoa1608664
34.
Sultan A, Perriard F, Macioce V, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. Diabetic Medicine. Published online 18 April 2017. doi:10.1111/dme.13364
35.
Soliman EZ, Backlund JYC, Bebu I, Orchard TJ, Zinman B, Lachin JM. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2017;40(6):793-799. doi:10.2337/dc16-2050
36.
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. 2017;40(6):809.3-809. doi:10.2337/dc17-er06e
37.
Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. New England Journal of Medicine. 2017;376(15):1419-1429. doi:10.1056/NEJMoa1610187
38.
Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 2017;376(15):1407-1418. doi:10.1056/NEJMoa1608664
39.
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine. 2017;377(3):300-301. doi:10.1056/NEJMc1706292
40.
Older antidiabetic drugs | The British Journal of Cardiology. https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/
41.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
42.
Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2017;377(13):1228-1239. doi:10.1056/NEJMoa1612917
43.
Pickering RJ, Rosado CJ, Sharma A, Buksh S, Tate M, de Haan JB. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology. 2018;7(4). doi:10.1002/cti2.1016
44.
Microvascular Complications and Foot Care. Diabetes Care. 2017;40(Supplement 1):S88-S98. doi:10.2337/dc17-S013
45.
Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. Published online 17 January 2017. doi:10.1136/bmj.i6505
46.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010;375(9733):2215-2222. doi:10.1016/S0140-6736(10)60484-9
47.
The changing face of diabetes complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109
48.
Wong MG, Perkovic V, Chalmers J, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694-700. doi:10.2337/dc15-2322
49.
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862
50.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors. Archives of Internal Medicine. 2011;171(5). doi:10.1001/archinternmed.2011.2
51.
Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes—whose agenda? The Lancet. 2011;377(9773):1220-1222. doi:10.1016/S0140-6736(10)61112-9
52.
Zhang CY, Sun AJ, Zhang SN, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine. 2010;42(4):305-315. doi:10.3109/07853891003796752
53.
Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal. 2015;36(34):2288-2296. http://eurheartj.oxfordjournals.org/content/36/34/2288
54.
Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38(9):1777-1803. doi:10.2337/dci15-0012
55.
Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? Current Diabetes Reports. 2013;13(3):403-410. doi:10.1007/s11892-013-0371-2
56.
Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care. 2015;38(2):316-322. doi:10.2337/dc14-0920
57.
Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;372(23):2197-2206. doi:10.1056/NEJMoa1414266
58.
Cefalu WT, Rosenstock J, LeRoith D, Blonde L, Riddle MC. Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”. Diabetes Care. 2016;39(5):664-667. doi:10.2337/dc16-0405
59.
Black JA, Sharp SJ, Wareham NJ, et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. British Journal of General Practice. 2014;64(621):e208-e216. doi:10.3399/bjgp14X677833
60.
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. doi:10.1007/s00125-009-1470-0
61.
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes & Endocrinology. 2017;5(6):431-437. doi:10.1016/S2213-8587(17)30104-3
62.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
63.
Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology. 2010;141(2):157-166. doi:10.1016/j.ijcard.2008.11.211
64.
Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? Clinical Diabetes. 2008;26(1). http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88
65.
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010;362(17):1563-1574. doi:10.1056/NEJMoa1001282
66.
Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. Current Vascular Pharmacology. 2017;15(999):1-1.
67.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis. 2016;252:207-274. doi:10.1016/j.atherosclerosis.2016.05.037
68.
White J, Swerdlow DI, Preiss D, et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology. 2016;1(6). doi:10.1001/jamacardio.2016.1884
69.
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036
70.
Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. http://www.nice.org.uk/guidance/cg127
71.
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010;362(17):1575-1585. doi:10.1056/NEJMoa1001286
72.
Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. The Lancet. 2012;380(9841):601-610. doi:10.1016/S0140-6736(12)60987-8
73.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ : British Medical Journal. 1998;317(7160). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/
74.
Whelton PK. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Archives of Internal Medicine. 2005;165(12). doi:10.1001/archinte.165.12.1401
75.
Barzilay JI, Davis BR, Pressel SL, et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes. 2012;5(2):153-162. doi:10.1161/CIRCOUTCOMES.111.962522
76.
Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 2002;359(9311):1004-1010. doi:10.1016/S0140-6736(02)08090-X
77.
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1
78.
Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal of the American College of Cardiology. 2010;56(1):77-85. doi:10.1016/j.jacc.2010.02.046
79.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet. 2007;369(9557):201-207. doi:10.1016/S0140-6736(07)60108-1
80.
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 2010;362(17):1575-1585. doi:10.1056/NEJMoa1001286
81.
Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia. 1996;39(12):1646-1654. doi:10.1007/s001250050629
82.
Bangalore S, Kumar S, Lobach I, Messerli FH. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. Circulation. 2011;123(24):2799-2810. doi:10.1161/CIRCULATIONAHA.110.016337
83.
Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine. 2005;165(12). doi:10.1001/archinte.165.12.1410
84.
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020
85.
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998
86.
Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020
87.
Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-418. doi:10.2337/dc16-2641
88.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3
89.
Adamsson Eryd S, Svensson AM, Franzén S, Eliasson B, Nilsson PM, Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabetic Medicine. 2017;34(3):411-418. doi:10.1111/dme.13266
90.
Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ. 2009;338(feb12 1):b441-b441. doi:10.1136/bmj.b441
91.
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. Published online 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
92.
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. Published online 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
93.
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. British Journal of Ophthalmology. Published online 7 March 2017. doi:10.1136/bjophthalmol-2016-310063
94.
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. Published online 21 April 2017. doi:10.2337/dc17-er06e
95.
Solomon SD, Chew E, Duh EJ, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418. Diabetes Care. Published online 21 April 2017. doi:10.2337/dc17-er06e
96.
Rosenberg JB, Tsui I. Screening for Diabetic Retinopathy. New England Journal of Medicine. 2017;376(16):1587-1588. doi:10.1056/NEJMe1701820
97.
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. New England Journal of Medicine. 2017;376(16):1507-1516. doi:10.1056/NEJMoa1612836
98.
Moreton RBR, Stratton IM, Chave SJ, Lipinski H, Scanlon PH. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. Diabetic Medicine. 2017;34(7):993-999. doi:10.1111/dme.13350
99.
Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology : Advances and Applications. 2016;8. doi:doi: 10.2147/CPAA.S82008
100.
Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayer WC, Nally JV. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. American Journal of Kidney Diseases. Published online February 2017. doi:10.1053/j.ajkd.2016.11.018
101.
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey. https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022
102.
Webb DR, Zaccardi F, Davies MJ, et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. Diabetes/Metabolism Research and Reviews. Published online 2016. doi:10.1002/dmrr.2877
103.
Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine. 2016;33(11):1466-1476. doi:10.1111/dme.13083
104.
Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabetic Medicine. Published online February 2017. doi:10.1111/dme.13324
105.
Johal S, Jackson-Spence F, Gillott H, et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. Diabetic Medicine. Published online 5 June 2017. doi:10.1111/dme.13383
106.
Clokie M, Greenway AL, Harding K, et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. Diabetic Medicine. 2017;34(3):305-315. doi:10.1111/dme.13313
107.
Game F. Classification of diabetic foot ulcers. Diabetes/Metabolism Research and Reviews. 2016;32:186-194. doi:10.1002/dmrr.2746
108.
Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: Clinical review. Journal of Tissue Viability. 2016;25(4):229-236. doi:10.1016/j.jtv.2016.06.005
109.
Boulton AJ, Jeffcoate WJ, Jones TL, Ulbrecht JS. International collaborative research on Charcot’s disease - 2009. The Lancet. 2009;373(9658):105-106. doi:10.1016/S0140-6736(09)60019-2
110.
Yavuz M, Ersen A, Hartos J, et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. Diabetes Care. 2017;40(2):e14-e15. doi:10.2337/dc16-2204
111.
P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. The British Journal of Radiology. 2015;88(1053). doi:doi: 10.1259/bjr.20150135
112.
Diabetic foot problems: prevention and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng19
113.
Holt RIG. Understanding of the causes and management of diabetic foot disease. Diabetic Medicine. 2017;34(3):303-304. doi:10.1111/dme.13319
114.
Jin D mei, Xu Y, Geng D feng, Yan T bin. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice. 2010;89(1):10-15. doi:10.1016/j.diabres.2010.03.021
115.
Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine. 2016;33(11):1466-1476. doi:10.1111/dme.13083
116.
Foresta C, Ferlin A, Lenzi A, Montorsi P. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. Andrology. Published online March 2017. doi:10.1111/andr.12342
117.
Azmi S, Ferdousi M, Alam U, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia. Published online 29 March 2017. doi:10.1007/s00125-017-4245-z
118.
Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. Published online 9 March 2017. doi:10.1136/heartjnl-2016-310746
119.
Omland T, Randby A, Hrubos-Strøm H, Røsjø H, Einvik G. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. The American Journal of Cardiology. 2016;118(12):1821-1825. doi:10.1016/j.amjcard.2016.08.070
120.
Braffett BH, Wessells H, Sarma AV. Urogenital Autonomic Dysfunction in Diabetes. Current Diabetes Reports. 2016;16(12). doi:10.1007/s11892-016-0824-5
121.
Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care. 2016;39(9):1587-1593. doi:10.2337/dc16-0059
122.
Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE. 2016;11(10). doi:doi: 10.1371/journal.pone.0157915
123.
Santi D, Granata ARM, Guidi A, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology. 2016;174(4):513-522. doi:10.1530/EJE-15-1100
124.
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
125.
Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321
126.
Malavige LS, Wijesekara P, Ranasinghe P, Levy JC. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research. 2015;20(1). doi:10.1186/s40001-015-0186-5
127.
Hotaling JM, Sarma AV, Patel DP, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care. 2016;39(9):1587-1593. doi:10.2337/dc16-0059
128.
Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). Current Diabetes Reports. 2017;17(5). doi:10.1007/s11892-017-0857-4
129.
Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime. https://wwww.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_
130.
Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabetic Medicine. 2012;29(4):420-433. doi:10.1111/j.1464-5491.2012.03582.x
131.
The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey. https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728
132.
Scott AR. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabetic Medicine. 2015;32(6):714-724. doi:10.1111/dme.12757
133.
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, ,. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792
134.
Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE. 2015;10(6). doi:doi: 10.1371/journal.pone.0126427
135.
Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care. 2015;38(2):316-322. doi:10.2337/dc14-0920
136.
Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279
137.
Zaccardi F, Webb DR, Davies MJ, et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia. Published online 17 March 2017. doi:10.1007/s00125-017-4235-1
138.
Zaccardi F, Webb DR, Davies MJ, et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. Diabetes, Obesity and Metabolism. Published online April 2017. doi:10.1111/dom.12941
139.
Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology. 2016;12(4):222-232. doi:10.1038/nrendo.2016.15
140.
Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nature Reviews Endocrinology. 2016;12(4):222-232. doi:10.1038/nrendo.2016.15
141.
Micha R, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA. 2017;317(9). doi:10.1001/jama.2017.0947
142.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi:10.2337/dc13-0331
143.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology. 2015;14(1). doi:10.1186/s12933-015-0260-x
144.
Nicolucci A, Standl E. Antiplatelet Therapy for Every Diabetic Person? Diabetes Care. 2011;34(Supplement_2):S150-S154. doi:10.2337/dc11-s210
145.
Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabetic Medicine. 2016;33(3):280-289. doi:10.1111/dme.12885
146.
The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check. http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/
147.
Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine. 2017;34(3):316-327. doi:10.1111/dme.13133
148.
Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabetic Medicine. 2014;31(7):764-772. doi:10.1111/dme.12428
149.
Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA. 317(8):825-835. doi:10.1001/jama.2017.0686
150.
Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626
151.
Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 1996. doi:10.1002/14651858.CD003267.pub2
152.
Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862
153.
Denig P, Schuling J, Haaijer-Ruskamp F, Voorham J. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ. 2014;349(sep25 6):g5651-g5651. doi:10.1136/bmj.g5651
154.
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care. 2017;40(7):813-820. doi:10.2337/dc16-2736
155.
Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017;40(7):821-831. doi:10.2337/dc17-0291
156.
Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine. Published online 13 July 2017. doi:10.1111/dme.13419
157.
Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. Diabetic Medicine. 2017;34(10):1447-1455. doi:10.1111/dme.13419
158.
Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, eds. Textbook of Diabetes. Fifth edition. Wiley Blackwell; 2017. http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056
159.
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354
